Navigation Links
Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
Date:10/23/2007

CALGARY, Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a clinical trial using intravenous administration of REOLYSIN(R) in combination with cyclophosphamide, a chemotherapeutic agent as well as immune modulator, in patients with advanced cancers. The Principal Investigators are Dr. James Spicer of King's College in London, Dr. Johann de Bono and Dr. Kevin Harrington of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, and Professor Hardev Pandha of the Royal Surrey County Hospital NHS Trust, Surrey and Mount Alvernia Hospitals.

The Company also intends to host a conference call Wednesday, October 24, 2007 to provide an update on its expanding clinical program. The dial-in details appear below.

"We are really looking forward to treating patients in this trial," said Principal Investigator Dr. James Spicer. "The hope is that it will provide valuable information about the relationship between oncolytic viral therapy and the immune response of the patient."

The trial (REO 012) is an open-label, dose-escalating, non-randomized trial of REOLYSIN(R) given intravenously with escalating doses of cyclophosphamide. A standard dose of REOLYSIN(R) is administered intravenously over five consecutive days, while an intravenous dose of cyclophosphamide is administered three days before REOLYSIN(R) treatment and continues through the course of the treatment cycle. The total number of patients studied will depend on the number of dose levels tested, but it is anticipated to be approximately 30 patients.

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours including pancreatic, lung and ovarian cancers that are refractory (have not responded) to stan
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 CSL Behring ... Administration has accepted for review the company,s Biologics License ... single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In ... Hemophilia A is a ... VIII; nearly all affected patients are male. People with ...
(Date:7/27/2015)... Calif. , July 27, 2015  Amgen (NASDAQ: ... its second quarter financial results on Thursday, July 30, ... The announcement will be followed by a conference call ... in the call from Amgen will be Robert ... other members of Amgen,s senior management team. ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... ... facility identification solutions, today announced a new video: 3 Ways to GHS ... Hazard Communication Standard and the Globally Harmonized System (GHS) by effectively labeling chemical ...
(Date:7/27/2015)... 27, 2015 The Brain & ... of its annual Klerman and Freedman Prizes, recognizing ... have been supported by NARSAD Young Investigator Grants. ... innovative ideas in neurobiological and psychosocial research, garner ... the early detection, treatment, prevention and cure of ...
Breaking Biology Technology:U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3Amgen Announces Webcast of 2015 Second Quarter Financial Results 2Brady Releases “3 Roads to GHS Labels” Video 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6
... , KYOTO, Japan and MARCY L,ETOILE, ... bioMerieux announce today that they have entered into a ... identification in microbiology laboratories. bioMerieux will work with Shimadzu ... MALDI-TOF* mass spectrometry technology for optimized integration into the ...
... 21 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, TSX:YM), ... will report results from several global nimotuzumab trials in adults ... cancer at the American Society of Clinical Oncology annual meeting ... Illinois . The trials are being conducted by Oncoscience AG ...
... led by chemists and engineers from the University of Pennsylvania ... membranes and that show promise in targeted delivery of cancer ... safely to the body in the emerging field called nanomedicine. ... of the journal Science . The research ...
Cached Biology Technology:Shimadzu and bioMerieux Enter into Partnership for Mass Spectrometry Applications in Microbiology 2Shimadzu and bioMerieux Enter into Partnership for Mass Spectrometry Applications in Microbiology 3Shimadzu and bioMerieux Enter into Partnership for Mass Spectrometry Applications in Microbiology 4YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting 2YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting 3YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting 4YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting 5Penn-led collaboration mimics library of bio-membranes for use in nanomedicine, drug delivery 2Penn-led collaboration mimics library of bio-membranes for use in nanomedicine, drug delivery 3
(Date:7/7/2015)... 30, 2015 Research ... addition of the "Capacitive Fingerprint Sensors Patent ... To this date, fingerprint sensing technology is the ... sensors are well developed. This patent landscape focuses ... The domain of capacitive fingerprint sensors is ...
(Date:7/2/2015)... , June 25, 2015 ... addition of the "Next Generation Biometrics Market by ... 2020" report to their offering. The ... Billion by 2020, at a CAGR of 17.9% between ... the leading application for the market. Safran SA ...
(Date:6/29/2015)... 2015 Research and Markets( ... "Latin America Biomedical Sensors Market - Growth, Trends & ... The Latin America Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
Breaking Biology News(10 mins):Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Latin America Biomedical Sensors Market Report 2015-2020 2
... parasites and assessing severity of disease is described in ... Medicine . Researchers led by Professor Nick White from ... dangerous type of malaria, falciparum malaria. Usually the severity ... parasites in the blood under the microscope, but this ...
... Engineered bug makes key chemical precursor from grain sorghum ... production method for succinate, a key ingredient of many ... University, the technology uses a genetically modified form of ... almost pure succinate. , Finding "green" methods to make ...
... on earth range from 3.5 million to over 30 ... and described. Estimating historical biodiversity from the fossil record ... ecologists - but not paleontologists - have traditionally relied ... a long-established rule of thumb called the species-area effect: ...
Cached Biology News:Bacteria are key to 'green' plastics, drugs 2Bacteria are key to 'green' plastics, drugs 3Space matters: Estimating species diversity in the fossil record 2
... Recognizes Nabeta2. The epitope ... present in any other known ... expected to work on human ... highly conserved (17/19 residues). Reactivity ...
Chicken polyclonal to HAGH ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to N terminal amino acids 110-260 of Human HAGH. Entrez GeneID: 3029 Swiss ...
Mouse monoclonal [SPM325] to Xanthine Oxidase, prediluted ( Abpromise for all tested applications). Antigen: C terminal 358 amino acid fragment of human xanthine oxidase. Entrez Gene ID: 749...
... Disrupts biological cells for DNA ... 96 well plates (includes 96 well ... consistent lysis across the entire plate ... wells). Can be used for ...
Biology Products: